louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00987012: The Influence of Fortified Pomegranate Juice (Punica Granatum) on Seasonal Influenza and Swine Flu Patients
Official title: The Influence of Fortified Pomegranate Juice (Punica Granatum) on Seasonal Influenza and Swine Flu Patients - A Prospective Randomized Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Influenza A
Swine Flu
Lead sponsor: Hillel Yaffe Medical Center
Sponsor class: OTHER_GOV
Collaborators: name: Gan shmuel Group
First posted: 2009-09-30
Enrollment: 200
Sex: ALL
Minimum age (years): 12
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: It has been shown in laboratory studies that pomegranate juice contains anti-viral action against influenza. The researchers wish to investigate the effect of pomegranate juice on patients suffering from influenza A (seasonal or swine flu).


Eligibility criteria: Inclusion Criteria:

* Individuals confirmed and suffering from Influenza A

Exclusion Criteria:

* Individuals suffering from influenza included in the high risk group

Primary outcomes:
measure: Early relief of influenza symptoms
timeFrame: Within one week
Secondary outcomes:
Other outcomes:
Locations:
city: Hadera
country: Israel
facility: Hillel Yaffe Medical Center
Study officials:
References:
Clinical trial NCT04993612: Postcapillary Blood Gas Analysis in Wedge Position (Wedge-BGA)
Official title: Blood Gas Analysis Obtained in Pulmonary Capillary Wedge Position During Right Heart Catheterization
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Pulmonary Hypertension
Lead sponsor: RWTH Aachen University
Sponsor class: OTHER
First posted: 2021-08-06
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: All patients receiving right heart catheterization for appropriate indications will be interviewed for their consent to participate in the study

Brief summary: If pulmonary hypertension is suspected, a right heart catheterization is usually performed to confirm or rule out the diagnosis. As part of this examination, blood samples are taken from various locations as standard and blood gas analyses are performed. One of the most important measurements during the right heart catheterization is the measurement of the pulmonary arterial occlusion pressure by the so-called wedge maneuver. To measure this value, the catheter with inflated balloon must be advanced into the pulmonary vessels until the "wedge" position is reached, i.e. the balloon completely occludes a branch of the pulmonary artery. In this study, the investigators want to characterize patients with pulmonary hypertension of different causes in more detail. To do that, two blood samples (totaling approximately 4 mL of blood, one sample directly after occlusion and the other one two minutes later) will be drawn during the right heart catheterization from the above-mentioned "wedge" position", behind the inflated balloon, and blood gas analyses will be performed on these samples. In addition, various clinical parameters (comorbidities, etc.) will be recorded by means of clinical questionnaires. Follow-up data will be analyzed and correlations with the aforementioned blood gas analyses will be examined. The results of the study will be used to more precisely characterize the still vague concept of secondary pulmonary hypertension. This could help to develop new therapeutic strategies in some subgroups in the future.


Eligibility criteria: Inclusion Criteria:

* Patients who have a clearly defined indication for Right heart catheterization.
* Age \> 18 years
* Informed consent for participation in the study will sign

Exclusion Criteria:

* Individuals who are not fully capable of giving consent and understanding the nature, significance, and scope of the study
* Pregnancy and lactation

Primary outcomes:
measure: Risk group after 3-6 months
timeFrame: 3-6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Aachen
country: Germany
facility: University Hospital RWTH Aachen
Study officials:
References:
Clinical trial NCT03830112: Effect of Two Pilates-based Mat Exercise Programs on the Isometric Strength of Core Muscles in Healthy Men
Official title: Effects of a Pilates-based Mat Exercise Program Compared to a Pilates-based Mat Exercise With Resistance Band on the Isometric Strength of Core Muscles, Lean Mass, and Body Fat in Men 18 to 25 Years
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy Volunteers
Lead sponsor: Universidad de Antioquia
Sponsor class: OTHER
First posted: 2019-02-05
Enrollment: 58
Sex: MALE
Minimum age (years): 18
Maximum age (years): 25
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Based on the current evidence, it is known that Pilates is an exercise technique that has been used mainly by women in sport, fitness and rehabilitation. Most research has been developed with women. The participation of men in the research studies is reduced and methodology rigor is low, therefore, there is insufficient evidence on the effects of this type of training in men, in addition, there are no studies that have proven the effects of a Pilates-based mat exercise with resistance band on strength of core muscles.

The main objective of this research is to identify the effects of a Pilates-based mat exercise program versus a Pilates-based exercise mat program with resistance band on the isometric strength of the core muscles in men 18 to 25 years.

Detailed description: Fifty-eight men will be randomly assigned to one of two Pilates exercise programs. Pilates-based mat exercise and Pilates-based mat exercise with Theraband® (blue color). Interventions will be performed three times a week for eight-weeks on alternate days. Half will perform Pilates-based mat exercise and the remaining 29 will perform Pilates-based mat exercise with Theraband®. Both groups complete eleven exercises from week one to four and twelve exercises from week five to eight.

Eligibility criteria: Inclusion Criteria:

* Healthy volunteers.
* Perform ≤150 minutes of aerobic exercise per week.

Exclusion Criteria:

* Perform any Pilates exercise previously.
* Smoker.
* History of asthma.
* History of diabetes.
* History of hypertension.
* History of cardiovascular disease.
* History of coronary heart disease.
* Arrhythmias.
* Under medical treatment with anticoagulants, beta-blockers, calcium antagonists, bronchodilators, and/or steroids.
* Psychological, neuromotor and/or osteo-muscular conditions that may affect participation in an exercise program.
* People with metal prosthesis.

Primary outcomes:
measure: Change in isometric strength of the core muscles
timeFrame: Baseline and after 8 weeks
Secondary outcomes:
measure: Change in lean mass
timeFrame: Baseline and after 8 weeks
measure: Change in body fat
timeFrame: Baseline and after 8 weeks
Other outcomes:
Locations:
city: Bogotá
country: Colombia
facility: Centro de Formación en Actividad Física y Cultura
state: Cundinamarca
Study officials:
affiliation: Universidad de Antioquia
name: Víctor H Arboleda Serna, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02686112: Pregnancy Outcome in Woman With Threatened Abortion
Official title: Pregnancy Outcome in Woman With Threatened Abortion
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Threatened Abortion
Lead sponsor: Bnai Zion Medical Center
Sponsor class: OTHER_GOV
First posted: 2016-02-19
Enrollment: 3000
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Women who attanded the Emergency department with vaginal bleeding and/or abdominal pain and were on their 20th week of pregnancy or less.

Brief summary: The study aims to quantify the relations between first \& second trimester bleeding and maternal \& neonatal morbidity. Additionally, the study will help in assessing the risk for abortions in women with threatened abortions and the risk factors for threatened abortion.

Detailed description: the study is following woman retrospectively through their pregnancy from the first trimester troughout delivery .

we will measure the relation between first and/or second trimester bleeding ( threatend abortion ) and pregnancy outcome ( as written below ) - maternal and neonatal .

Eligibility criteria: Inclusion Criteria:

* Women who attended the Emergency department with vaginal bleeding and/or abdominal pain and were on their 20th week of pregnancy or less.

Exclusion Criteria:

* Women with any background that can explain vaginal bleeding or any other circumstance that can explain it.

Primary outcomes:
measure: Maternal and neonatal outcome in pregnancies with 1st and 2nd trimester bleeding
timeFrame: 9 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Bnai Zion
name: Eyal Levy, Resident
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04230512: Hybrid Pump Technology
Official title: Hybrid Electrical-Mechanical Pump for Vacuum Suspension of Prosthetic Sockets
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Amputation
Keywords: Amputation
Prosthesis
Gait
Leg
Lead sponsor: VA Office of Research and Development
Sponsor class: FED
First posted: 2020-01-18
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: Randomly assigned conditions of pump function to characterize the effects of added movement on socket-reaction torques
Primary purpose: BASIC_SCIENCE

Brief summary: Prostheses can be suspended from the amputated limb using a variety of techniques, such as straps and suction. Suspending the prosthesis by creating a vacuum between the prosthetic socket and limb using a pump has benefits over other techniques including improved limb health and mobility. A new pump design will be tested by prosthesis users in the laboratory to verify its functionality during walking.

Detailed description: Human subject testing will involve a cross-sectional, repeated measures study consisting of a single 3 hour visit wherein participants will initially stand and then continuously walk at their self-selected speed for ten minutes on a level treadmill with the prototype under two randomly presented conditions of the mechanical system: 1) fully functional, and 2) locked to restrict axial displacement. After written informed consent is obtained, information on socket comfort and mobility capability will be collected. A load-cell will be installed proximal to the prototype and in-line with the prosthesis to measure instantaneous socket-reaction moments.

Eligibility criteria: Inclusion Criteria:

* Ability to stand quietly and walk for 10 minutes continuously without an assistive device (e.g. cane or walker) and without undue fatigue or health risks
* Pre-classified clinically to be at least a limited community ambulator of Medicare Functional Classification Level (K)2
* Residual limb in good health
* At least six months experience with a definitive prosthesis that utilizes vacuum assisted suspension

Exclusion Criteria:

* Pathologies aside from amputation or taking medicine that would influence walking or balance
* Poor prosthetic fit or poor residual limb sensation

Primary outcomes:
measure: Socket-reaction moments
timeFrame: Immediate
Secondary outcomes:
measure: Socket Comfort
timeFrame: Immediate
measure: Perceived mobility capability
timeFrame: Immediate
Other outcomes:
Locations:
city: Chicago
country: United States
facility: Jesse Brown VA Medical Center, Chicago, IL
state: Illinois
Study officials:
affiliation: Jesse Brown VA Medical Center, Chicago, IL
name: Matthew J. Major, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04615312: A Trail of CDK4 / 6 Inhibitor and MEK Inhibitor in the Treatment of Metastatic Digestive System Tumors
Official title: Phase I Clinical Study on the Safety and Tolerability of a CDK4 / 6 Inhibitor and a MEK Inhibitor in the Treatment of Metastatic Digestive System Tumors
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Digestive System Tumors
Lead sponsor: Henan Cancer Hospital
Sponsor class: OTHER_GOV
First posted: 2020-11-04
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a prospective, open, phase I clinical study to evaluate the safety and tolerability of a CDK4 / 6 inhibitor and a MEK inhibitor in the treatment of metastatic digestive system tumors


Eligibility criteria: Inclusion Criteria:

1. Aged 18-75 years;
2. ECOG score ≤ 1;
3. Patients with advanced KRAS mutation or metastatic digestive system tumor confirmed by histology or cytology and imaging diagnosis;
4. According to Recist1.1, there was at least one measurable lesion;
5. The expected survival time was more than 12 weeks;

Exclusion Criteria:

1. Patients who received any anti-tumor treatment within 4 weeks before enrollment, including radiotherapy, chemotherapy, molecular targeted therapy and immunotherapy, or participated in another intervention clinical trial;
2. Previous treatment with targeted BRAF, MEK, ERK or CDK family related inhibitors;
3. The third space effusion (such as massive pleural effusion or ascites) with clinical symptoms that cannot be controlled by drainage or other methods;
4. Allergy to any test drug and its excipients, or serious allergic history, or contraindication of the test drug;
5. Have a history of immunodeficiency, including HIV positive, or other acquired, congenital immunodeficiency diseases, or a history of organ transplantation;

Primary outcomes:
measure: To determine the maximum tolerated dose of a CDK4 / 6 inhibitor and a MEK inhibitor therapy
timeFrame: Up to approximately 24 months
Secondary outcomes:
measure: ORR
timeFrame: Up to approximately 24 months
Other outcomes:
Locations:
city: Zhengzhou
country: China
facility: Henan Cancer Hospital
state: Henan
Study officials:
affiliation: Henan Cancer Hospital
name: Ning Li, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Henan Cancer Hospital
name: Suxia Luo, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05145712: Quantitative Bowel Readiness Assessment System in Predicting the Missed Detection Rate of Adenomas
Official title: A Single-center Study of an AI-assisted Quantitative Bowel Readiness Assessment System in Predicting the Missed Detection Rate of Adenomas Under Colonoscopy
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Self Control
Prospective
Interventional
Lead sponsor: Renmin Hospital of Wuhan University
Sponsor class: OTHER
First posted: 2021-12-06
Enrollment: 263
Sex: ALL
Minimum age (years): 45
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: To verify the correlation between the proposed artificial intelligence based bowel preparation assessment system and the missed detection rate of adenomas, and to evaluate whether the system can effectively assist doctors in identifying patients who need to be re-examined by colonoscopy due to poor intestinal cleanliness.


Eligibility criteria: Inclusion Criteria:

At least 4 operators were included in this study, and the operating years of colonoscopy were ≥ 5 years, and the number of independent operating cases was ≥ 3000.

Subjects who meet all of the following specific criteria will be considered for participation in the study:

1. Male or female with age ≥ 45 years inclusive;
2. Able to read, understand and sign informed consent;
3. The investigator believes that the subjects can understand the process of the clinical study, are willing and able to complete all study procedures and follow-up visits, and cooperate with the study procedures.

Exclusion Criteria:

Subjects who meet any of the following specific criteria will be refused to participate in the study:

1. have a history of drug or alcohol abuse or psychological disorders within the last 5 years;
2. Pregnant or lactating women;
3. Patients with known multiple polyp syndrome;
4. patients with known inflammatory bowel disease;
5. known intestinal stenosis or space-occupying tumor;
6. known colon obstruction or perforation;
7. patients with a history of colorectal surgery;
8. Patients with previous history of allergy to pre-used spasmolysis;
9. Unable to perform biopsy and polyp removal due to coagulation disorders or oral anticoagulants;
10. High risk diseases or other special conditions that the investigator considers the subject unsuitable for participation in the clinical trial.

Primary outcomes:
measure: Missed detection rate of ≥5mm adenoma
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Wuhan
country: China
facility: Renmin Hospital of Wuhan University
state: Hubei
Study officials:
affiliation: Renmin Hospital of Wuhan University
name: Honggang Yu, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04952012: The Effect of Thyroid Antibodies on Female Reproductive Function and Pregnancy Outcomes
Official title: The Effect of Thyroid Antibodies on Female Reproductive Function and Pregnancy Outcomes
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Thyroiditis, Autoimmune
Lead sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Sponsor class: OTHER
Collaborators: name: First People's Hospital of Yuhang
name: Taizhou Women and Children's Hospital Affiliated to Wenzhou Medical University
name: Changxing People's Hospital
First posted: 2021-07-07
Enrollment: 4000
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Subjects were all in the 1st trimester of pregnancy.

Brief summary: Some women at reproductive age have positive antithyroid antibodies (ATAs). Thyroid peroxidase antibody (TPOAb) and thyroglobulin antibody (TgAb) are the most common ATAs. This study aimed to evaluate the impact of ATAs on maturation of women reproductive system and pregnancy outcomes.


Eligibility criteria: Inclusion Criteria:

* Age during 18-45y;
* Women tested for TPOAb and/or TgAb, TSH, free T3, free T4, total T3 and total T4 during the 1st trimester of pregnancy

Exclusion Criteria:

* Multiple pregnancies;
* Age \< 18 y or \> 40 y;
* L-T4 or PTU intervention before pregnancy;
* Other autoimmune diseases.

Primary outcomes:
measure: Incidence rate of pregnancy complications in women with or without thyroid antibodies
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Hangzhou
country: China
facility: Second Affiliated Hospital, School of Medicine, Zhejiang University
state: Zhejiang
Study officials:
References:
Clinical trial NCT02305212: Cogmed for Working Memory After TBI
Official title: Applying Cogmed to Improve Working Memory Abilities After Traumatic Brain Injury
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Traumatic Brain Injury
Keywords: Working Memory
Lead sponsor: Kessler Foundation
Sponsor class: OTHER
First posted: 2014-12-02
Enrollment: 12
Sex: ALL
Minimum age (years): 9
Maximum age (years): 59
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: This study will examine a cognitive rehabilitation protocol targeted at working memory deficits for adults and children with Traumatic Brain Injury (TBI). In this randomized clinical trial, the efficacy of Cogmed, a cognitive rehabilitation protocol designed to improve working memory, will be examined in children with TBI. Neuropsychological and daily life functioning will be measured. Participants will be children (N=20) and adults (N=20) with a documented history of TBI. Participants will be randomized to a treatment group or a wait list control group. The Experimental Group will receive the Cogmed working memory training program 30-40 minutes per day, 5 days a week for 5 weeks for a total training time of approximately 15 hours. The Control Group will be a wait list control group that will cross over into treatment after the follow-up assessment. All subjects will undergo repeat assessments following completion of the working memory training protocol after the 7th week and again at 13 weeks to document changes in working memory performance.


Eligibility criteria: Inclusion Criteria:

* History of Traumatic Brain Injury

Exclusion Criteria:

* Diagnosis of other neurological conditions

Primary outcomes:
measure: Change in scores on standardized tests of working memory
timeFrame: Three points in time: Baseline assessment, Week 7 and Week 13
Secondary outcomes:
measure: Change in scores on self report measures of emotional functioning, assessed via questionnaire
timeFrame: Three points in time: Baseline assessment, Week 7 and Week 13
measure: Change in scores on self report measures of memory functioning, assessed via questionniare
timeFrame: Three points in time: Baseline assessment, Week 7 and Week 13
measure: Change in scores on self report measures of quality of life, assessed via questionnaire
timeFrame: Three points in time: Baseline assessment, Week 7 and Week 13
Other outcomes:
Locations:
city: Mountainside
country: United States
facility: Childrens Specialized Hosptial
state: New Jersey
city: West Orange
country: United States
facility: Kessler Foundation
state: New Jersey
Study officials:
affiliation: Kessler Fondation
name: Nancy Chiaravalloti, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04217512: Pantoprazole in Cisplatin Nephrotoxicity
Official title: Possible Protective Effect of Pantoprazole in Cisplatin Induced Nephrotoxicity in Patients With Head and Neck Cancer
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE3
Conditions: Oncology
Lead sponsor: Tanta University
Sponsor class: OTHER
First posted: 2020-01-03
Enrollment: 60
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Pantoprazole in Cisplatin Nephrotoxicity

Detailed description: Pantoprazole in Cisplatin NephrotoxicityPantoprazole in Cisplatin Nephrotoxicity. Is it protective?

Eligibility criteria: Inclusion Criteria:

* Patients with head and neck cancer

Exclusion Criteria:

* GFR less than 59.
* DM
* Elevated liver enzymes more than 3 fold.

Primary outcomes:
measure: Number of patients with no renal toxicity
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Tanta
country: Egypt
facility: Sherief Abd-Elsalam
Study officials:
affiliation: Demonstrator of Clinical Pharmacy
name: Eman M Ghonaim, Msc
role: PRINCIPAL_INVESTIGATOR
affiliation: Tanta University
name: Sahar El-Haggar, Prof
role: PRINCIPAL_INVESTIGATOR
affiliation: Tanta University
name: Suzy Goher, Lecturer
role: PRINCIPAL_INVESTIGATOR
References: